Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03522142
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT03514407
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇮🇹Istituto Ortopedico Rizzoli, Bologna, Italy
Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Drug: Corticosteroid
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT03497273
- Locations
- 🇯🇵
JA-Aichi Anjo Kosei Hospital, Anjo-Shi, Aichi, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa-Ken, Japan
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
- Conditions
- B-cell Lymphoma
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT03424122
- Locations
- 🇺🇸
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Arizona Cancer Center - Out Pt., Tucson, Arizona, United States
🇺🇸Texas Oncology, Austin, Texas, United States
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
- Conditions
- UC (Urothelial Cancer)
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT03374488
- Locations
- 🇫🇷
Centre de Lutte Contre le Cancer Francois Baclesse, Caen, France
🇫🇷Clinique Victor Hugo, Le Mans, France
🇫🇷Centre Leon Berard, Lyon, France
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
- Conditions
- UC (Urothelial Cancer)
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 93
- Registration Number
- NCT03361865
- Locations
- 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Tennessee Medical Center Knoxville, Knoxville, Tennessee, United States
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT03361228
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 89
- Registration Number
- NCT03358472
- Locations
- 🇺🇸
U of Kansas Cancer Center, Westwood, Kansas, United States
🇦🇺Royal Brisbane & Women s Hospital, Herston, Queensland, Australia
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03348904
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 11
- Registration Number
- NCT03347123
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States